EGFR N771delinsGY

CI-VAR-00002943Explore in graph →CIViC 1581

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma3
EGFR N771delinsGY	Dacomitinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID12420 In an in vitro study, MCF-7 cells expressing the EGFR N771delinsGY (N771GY) mutation demonstrated sensitivity to dacomitinib (PF00299804), with YFP-EGFR-ICD relocation observed at 50 nM. In comparison… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic
EGFR N771delinsGY	Erlotinib	Predictive	C	Supports Resistance	—	submitted	EID4671 In a stage III lung adenocarcinoma patient of African-American descent with EGFR N771>GY mutation, EGFR N771>GY was reported to be resistant to erlotinib treatment. The patient was treated with 4 cycl… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.